EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations

Marie Morfouace, Franck Bielle, Evangelia Razis, Florian Estrade, Alba Rubio, Francisco Bautista, Teresa de Rojas, Maria Vieito, Sara Meade, Marc Sanson, Andreia Capela Marques, Matthias Preusser und 13 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115493 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Marie Morfouace und 24 weiteren Autor:innen. Beteiligte Einrichtung: EORTC Headquarters, Brussels, Belgium; Gustave Roussy, Villejuif, France. Hauptthemen laut MEDLINE: Glioma, Germ-Line Mutation, Biomarkers, Tumor, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alliance Healthcare, Walgreens Boots Alliance, EORTC Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Adolescent and young adult (AYA) high grade gliomas (HGG) have the worst survival of AYA malignancies yet are poorly represented in large-scale molecular datasets. METHODS: 50 AYAs aged 12-29 with newly diagnosed or recurrent HGG and other high risk central nervous system (CNS) tumours were prospectively recruited to the EORTC SPECTA platform study and underwent whole exome sequencing, RNA sequencing and methylation profiling, with central pathological review. Actionable mutations were reported and patients followed up for therapies and outcome. RESULTS: From 46 locally diagnosed HGGs and 4 other recurrent CNS tumours, molecular and pathology review resulted in histological grade re-classification (n = 10), diagnostic refinement (n = 9) and revised diagnoses (n = 12) in a substantial proportion. Pathogenic constitutional alterations were present in 14 % overall and were largely limited to cases with IDH-wildtype glioblastoma and paediatric-type diffuse HGGs. 91 % of HGGs had potentially actionable alterations affecting RAS/RAF/MAPK (60 %), PI3K/AKT/mTOR (27 %) and cell cycle genes (11 %). High tumour mutational burden (> 10 somatic non-synonymous mutations per Mb of genome targeted) was present in 12 % at diagnosis and 18 % at recurrence, all in histological grade 4 tumours. Ten patients' treatment was modified on the basis of molecular profile, of whom 5 remained on treatment at last follow-up. CONCLUSION: AYA HGGs comprise a diverse group of entities; accurate, molecularly-defined diagnosis is critical to direct primary treatment, determine risk of genetic predisposition and guide molecularly-directed therapy. Current services fail to routinely address diagnosis, personalised molecular profiling or investigation of therapeutic opportunities for this high risk, poor prognosis group of rare cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaGerm-Line MutationBiomarkers, TumorBrain NeoplasmsHumansAdolescentYoung AdultMaleFemaleAdultChildNeoplasm GradingProspective StudiesExome SequencingDNA MethylationGenetic Predisposition to Disease

Stichwörter der Autor:innen

AYAActionable alterationsAdolescentConstitutional mutationsHigh grade gliomaYoung adult

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • EORTC Headquarters, Brussels, Belgium; Gustave Roussy, Villejuif, France.
  • Sorbonne Université, Paris Brain Institute-ICM, Inserm, CNRS, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Department of Neuropathology, Paris, France.
  • Third Medical Oncology Dept, Hygeia Hospital, Athens, Greece.
  • Centre Eugène Marquis, Rennes, France.
  • Hospital Niño Jesús, Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, Madrid, Spain.
  • Hospital Niño Jesús, Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, Madrid, Spain; Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Förderung

  • Alliance Healthcare
  • Walgreens Boots Alliance
  • EORTC Cancer Research Fund
  • Fonds Cancer
  • Walgreen Boots Alliance

Zitieren

APA

Morfouace, M., Bielle, F., Razis, E., Estrade, F., Rubio, A., Bautista, F., de Rojas, T., Vieito, M., Meade, S., Sanson, M., Marques, A. C., Preusser, M., Hatcher, H., Balasubramanian, G. P., Pineda, E., D'Hondt, L., Duerinck, J., Michotte, A., Mawrin, C., …, & McCabe, M. G. (2025). Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115493

Vancouver

Morfouace M, Bielle F, Razis E, Estrade F, Rubio A, Bautista F, et al. Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115493

BibTeX
@article{Morfouace2025,
  author = {Morfouace, Marie and Bielle, Franck and Razis, Evangelia and Estrade, Florian and Rubio, Alba and Bautista, Francisco and de Rojas, Teresa and Vieito, Maria and Meade, Sara and Sanson, Marc and Marques, Andreia Capela and Preusser, Matthias and Hatcher, Helen and Balasubramanian, Gnana Prakash and Pineda, Estela and D'Hondt, Lionel and Duerinck, Johnny and Michotte, Alex and Mawrin, Christian and Ribalta, Teresa and Marucci, Gianluca and Golfinopoulos, Vassilis and Pfister, Stefan M and Jones, David Tw and McCabe, Martin G},
  title = {Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115493}
}
Kostenlos starten →